English

ROCKET PHARMACEUTICALS, INC.

EDGAR

ITEK Quarterly report (10-Q) · filed 2026-08-10

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-39.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -85007000 USD Source
Operating Cash Flow: -45394000 USD Source

Free cash flow

-39.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -85007000 USD Source
Operating Cash Flow: -45394000 USD Source
Capital Expenditure: 101000 USD Source
Capital Expenditure: 93000 USD Source

Cash and cash equivalents: 225 million USD 2026-06-30 Source
Exact value

224507000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 110 million shares 2026-06-30 Source
Exact value

109539424 shares

Reported share-count change

1.53% · 1.66 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

107884420 shares · 2025-06-30· Source
109539424 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#2987866 Filing: 000119312526076551 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#2989172 Filing: 000119312526076551
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 35.62 million

Prior period

−USD 258.75 million

2024-01-01 – 2024-12-31
Current period

−USD 223.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-223123000 − -258746000 = 35623000 USD

-258746000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-223123000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Year-over-year change in Net income: 35623000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -223123000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#3023435 Filing: 000119312526076551 Input fundies:NetIncome: -258746000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#3024940 Filing: 000119312526076551
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 19.71 million

Prior period

−USD 209.72 million

2024-01-01 – 2024-12-31
Current period

−USD 190.01 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-190014000 − -209724000 = 19710000 USD

-209724000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-190014000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Year-over-year change in Operating cash flow: 19710000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -190014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1779941 Filing: 000119312526076551 Input fundies:OperatingCashFlow: -209724000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1781448 Filing: 000119312526076551
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-92.5%

Prior period

USD 5.86 million

2024-01-01 – 2024-12-31
Current period

USD 440,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

440000 − 5862000 = -5422000 USD

5862000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
440000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Year-over-year change in Capital expenditure: -5422000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 440000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1791780 Filing: 000119312526076551 Input fundies:CapitalExpenditure: 5862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1793274 Filing: 000119312526076551
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 231.75 million
Operating income −USD 231.75 million
Tax, interest and other Derived −USD 8.62 million
Net income −USD 223.12 million

Cash

Operating cash flow −USD 190.01 million
Capital expenditure USD 440,000
Free cash flow Derived −USD 190.45 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	167248000 Derived	-167248000	1821000 Derived	-169069000	-128783000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -167248000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -169069000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -121163000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 7620000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	224343000 Derived	-224343000	-2480000 Derived	-221863000	-186500000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -224343000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -221863000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -178142000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 8358000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	259659000 Derived	-259659000	-14064000 Derived	-245595000	-211352000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -259659000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -245595000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -194916000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 16436000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	273205000 Derived	-273205000	-14459000 Derived	-258746000	-215586000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -273205000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -258746000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -209724000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 5862000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	231747000 Derived	-231747000	-8624000 Derived	-223123000	-190454000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -231747000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -223123000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -190014000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 440000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source
20252025-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	Not reported	Operating Income: -167248000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -224343000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -259659000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -273205000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -231747000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -169069000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -221863000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -245595000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -258746000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -223123000 Open source Revenue: 0 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -121163000 Open source Capital Expenditure: 7620000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -178142000 Open source Capital Expenditure: 8358000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -194916000 Open source Capital Expenditure: 16436000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -209724000 Open source Capital Expenditure: 5862000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -190014000 Open source Capital Expenditure: 440000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -190M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-121163000	Operating Cash Flow: -121163000 Open source
20222022-12-31	Operating cash flow	-178142000	Operating Cash Flow: -178142000 Open source
20232023-12-31	Operating cash flow	-194916000	Operating Cash Flow: -194916000 Open source
20242024-12-31	Operating cash flow	-209724000	Operating Cash Flow: -209724000 Open source
20252025-12-31	Operating cash flow	-190014000	Operating Cash Flow: -190014000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -190.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-128783000	Operating Cash Flow: -121163000 Open source Capital Expenditure: 7620000 Open source
20222022-12-31	Free cash flow	-186500000	Operating Cash Flow: -178142000 Open source Capital Expenditure: 8358000 Open source
20232023-12-31	Free cash flow	-211352000	Operating Cash Flow: -194916000 Open source Capital Expenditure: 16436000 Open source
20242024-12-31	Free cash flow	-215586000	Operating Cash Flow: -209724000 Open source Capital Expenditure: 5862000 Open source
20252025-12-31	Free cash flow	-190454000	Operating Cash Flow: -190014000 Open source Capital Expenditure: 440000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

16.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Liabilities / assets	Not reported	No source recorded
20222022-12-31	Liabilities / assets	11.3%	Total Liabilities: 62121000 Open source Total Assets: 551807000 Open source
20232023-12-31	Liabilities / assets	13%	Total Liabilities: 73767000 Open source Total Assets: 566341000 Open source
20242024-12-31	Liabilities / assets	12.2%	Total Liabilities: 64466000 Open source Total Assets: 527700000 Open source
20252025-12-31	Liabilities / assets	16.1%	Total Liabilities: 53228000 Open source Total Assets: 330449000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.38× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Current assets / current liabilities	Not reported	No source recorded
20222022-12-31	Current assets / current liabilities	9.29×	Current Assets: 364060000 Open source Current Liabilities: 39169000 Open source
20232023-12-31	Current assets / current liabilities	7.8×	Current Assets: 378222000 Open source Current Liabilities: 48505000 Open source
20242024-12-31	Current assets / current liabilities	9.3×	Current Assets: 378183000 Open source Current Liabilities: 40684000 Open source
20252025-12-31	Current assets / current liabilities	6.38×	Current Assets: 192734000 Open source Current Liabilities: 30206000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 67.98 million Exact value Exact value: -67982000 USD 2015-01-01 – 2015-12-31: -67982000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2015-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -67982000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -67982000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459017004532/itek-20161231.xml#150632 Filing: 000156459017004532 The citation records this snapshot. The page link may show a newer release later.	−USD 17.42 million Exact value Exact value: -17416000 USD 2015-01-01 – 2015-12-31: -17416000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2015-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -17416000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17416000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459017004532/itek-20161231.xml#179182 Filing: 000156459017004532 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 42.85 million Exact value Exact value: -42854000 USD 2016-01-01 – 2016-12-31: -42854000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2016-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -42854000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42854000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-20171231.xml#113749 Filing: 000156459018004621 The citation records this snapshot. The page link may show a newer release later.	−USD 37.27 million Exact value Exact value: -37266000 USD 2016-01-01 – 2016-12-31: -37266000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2016-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -37266000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37266000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-20171231.xml#130869 Filing: 000156459018004621 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 29.5 million Exact value Exact value: -29497000 USD 2017-01-01 – 2017-12-31: -29497000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2017-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -29497000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29497000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-20171231.xml#113595 Filing: 000156459018004621 The citation records this snapshot. The page link may show a newer release later.	−USD 26.11 million Exact value Exact value: -26112000 USD 2017-01-01 – 2017-12-31: -26112000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2017-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -26112000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26112000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-20171231.xml#130617 Filing: 000156459018004621 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 169.07 million Exact value Exact value: -169069000 USD 2021-01-01 – 2021-12-31: -169069000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2021-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -169069000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -169069000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-20231231.htm#1777679 Filing: 000095017024021096 The citation records this snapshot. The page link may show a newer release later.	−USD 121.16 million Exact value Exact value: -121163000 USD 2021-01-01 – 2021-12-31: -121163000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2021-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -121163000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -121163000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-20231231.htm#1842078 Filing: 000095017024021096 The citation records this snapshot. The page link may show a newer release later.	USD 7.62 million Exact value Exact value: 7620000 USD 2021-01-01 – 2021-12-31: 7620000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ROCKET PHARMACEUTICALS, INC. · 2021-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Capital Expenditure: 7620000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7620000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-20231231.htm#1866260 Filing: 000095017024021096 The citation records this snapshot. The page link may show a newer release later.	−USD 128.78 million Calculation and evidence -121163000 − 7620000 USD Exact free cash flow: -128783000 USD 2021-01-01 – 2021-12-31: -121163000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 7620000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ROCKET PHARMACEUTICALS, INC. · 2021-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Free cash flow: -128783000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -121163000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-20231231.htm#1842078 Filing: 000095017024021096 Input fundies:CapitalExpenditure: 7620000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-20231231.htm#1866260 Filing: 000095017024021096 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 221.86 million Exact value Exact value: -221863000 USD 2022-01-01 – 2022-12-31: -221863000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2022-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -221863000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -221863000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#3336617 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	−USD 178.14 million Exact value Exact value: -178142000 USD 2022-01-01 – 2022-12-31: -178142000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2022-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -178142000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -178142000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2067546 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	USD 8.36 million Exact value Exact value: 8358000 USD 2022-01-01 – 2022-12-31: 8358000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ROCKET PHARMACEUTICALS, INC. · 2022-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Capital Expenditure: 8358000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8358000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2091531 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	−USD 186.5 million Calculation and evidence -178142000 − 8358000 USD Exact free cash flow: -186500000 USD 2022-01-01 – 2022-12-31: -178142000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8358000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ROCKET PHARMACEUTICALS, INC. · 2022-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Free cash flow: -186500000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -178142000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2067546 Filing: 000095017025029002 Input fundies:CapitalExpenditure: 8358000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2091531 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 245.6 million Exact value Exact value: -245595000 USD 2023-01-01 – 2023-12-31: -245595000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2023-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -245595000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -245595000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#3335198 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	−USD 194.92 million Exact value Exact value: -194916000 USD 2023-01-01 – 2023-12-31: -194916000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2023-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -194916000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -194916000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2066125 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	USD 16.44 million Exact value Exact value: 16436000 USD 2023-01-01 – 2023-12-31: 16436000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ROCKET PHARMACEUTICALS, INC. · 2023-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Capital Expenditure: 16436000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16436000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2090120 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.	−USD 211.35 million Calculation and evidence -194916000 − 16436000 USD Exact free cash flow: -211352000 USD 2023-01-01 – 2023-12-31: -194916000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 16436000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ROCKET PHARMACEUTICALS, INC. · 2023-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Free cash flow: -211352000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -194916000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2066125 Filing: 000095017025029002 Input fundies:CapitalExpenditure: 16436000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000095017025029002/rckt-20241231.htm#2090120 Filing: 000095017025029002 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 258.75 million Exact value Exact value: -258746000 USD 2024-01-01 – 2024-12-31: -258746000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2024-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -258746000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -258746000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#3024940 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	−USD 209.72 million Exact value Exact value: -209724000 USD 2024-01-01 – 2024-12-31: -209724000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2024-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -209724000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -209724000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1781448 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	USD 5.86 million Exact value Exact value: 5862000 USD 2024-01-01 – 2024-12-31: 5862000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ROCKET PHARMACEUTICALS, INC. · 2024-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Capital Expenditure: 5862000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1793274 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	−USD 215.59 million Calculation and evidence -209724000 − 5862000 USD Exact free cash flow: -215586000 USD 2024-01-01 – 2024-12-31: -209724000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 5862000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ROCKET PHARMACEUTICALS, INC. · 2024-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Free cash flow: -215586000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -209724000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1781448 Filing: 000119312526076551 Input fundies:CapitalExpenditure: 5862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1793274 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 223.12 million Exact value Exact value: -223123000 USD 2025-01-01 – 2025-12-31: -223123000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Net Income: -223123000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -223123000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#3023435 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	−USD 190.01 million Exact value Exact value: -190014000 USD 2025-01-01 – 2025-12-31: -190014000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Operating Cash Flow: -190014000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -190014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1779941 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	USD 440,000 Exact value Exact value: 440000 USD 2025-01-01 – 2025-12-31: 440000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Capital Expenditure: 440000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 440000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1791780 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.	−USD 190.45 million Calculation and evidence -190014000 − 440000 USD Exact free cash flow: -190454000 USD 2025-01-01 – 2025-12-31: -190014000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 440000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ROCKET PHARMACEUTICALS, INC. · 2025-12-31 ROCKET PHARMACEUTICALS, INC. (edgar:1281895) Free cash flow: -190454000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:43:34Z Snapshot: 3b6726f905f6232608853fa1153e077b58adce59eab70d76a586a7e06da4ce4d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1281895?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -190014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1779941 Filing: 000119312526076551 Input fundies:CapitalExpenditure: 440000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm#1791780 Filing: 000119312526076551 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

70 filings · 3,087 latest values · 3,087 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001281895, 1281895, ITEK, RCKT, edgar:1281895

Also known as INOTEK PHARMACEUTICALS CORP, Inotek Pharmaceuticals Corporation, ROCKET PHARMACEUTICALS, INC., Rocket Pharmaceuticals, Inc.

ROCKET PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation